Cargando…

Mechanistic Insights into Polyphenols’ Aggregation Inhibition of α-Synuclein and Related Peptides

[Image: see text] While several polyphenols were found to either inhibit or modulate the aggregation of proteins implicated in neurodegenerative diseases, such as Parkinson’s disease (PD), discrepant action mechanisms have been reported. This, in addition to some polyphenols’ pan-assay interference...

Descripción completa

Detalles Bibliográficos
Autores principales: Martins, G. F., Nascimento, C., Galamba, N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197135/
https://www.ncbi.nlm.nih.gov/pubmed/37125909
http://dx.doi.org/10.1021/acschemneuro.3c00162
_version_ 1785044488942518272
author Martins, G. F.
Nascimento, C.
Galamba, N.
author_facet Martins, G. F.
Nascimento, C.
Galamba, N.
author_sort Martins, G. F.
collection PubMed
description [Image: see text] While several polyphenols were found to either inhibit or modulate the aggregation of proteins implicated in neurodegenerative diseases, such as Parkinson’s disease (PD), discrepant action mechanisms have been reported. This, in addition to some polyphenols’ pan-assay interference compounds’ reputation, casts some doubts concerning their therapeutic relevance. Here, we studied, through molecular dynamics and enhanced sampling methods, the aggregation of 11-mer peptides from the non-amyloid-β component, an aggregation-prone domain of α-synuclein (α-syn) implicated in PD and other synucleinopathies, in neat water and aqueous solutions of resveratrol (RSV) and gallic acid (GA). Further, simulations of the complete protein were carried out in aqueous urea, RSV, and GA solutions. Our results show that peptide aggregation is not disrupted by either phenolic compound. Thus, instead, intrusion of RSV and GA in the inter-peptide region induces a peptide–peptide re-orientation, favoring terminal interactions that manifest in the formation of barrierless solvent-separated configurations. Moreover, although the (poly)phenols induce a pronounced peptide dewetting at high concentrations, β-sheet-rich regions, a hallmark of α-syn aggregation, are not disrupted. Thus, our results indicate that, if anything, RSV and GA delay or modulate peptide aggregation at high concentrations via the stabilization of solvent-separated conformations as opposed to aggregation inhibition. Structural analysis of the full protein, however, shows that the (poly)phenols induce more extended conformations of α-syn, similar to urea, possibly also influencing its aggregation propensity. However, opposite to urea, the (poly)phenols reduce α-syn’s conformational space, likely due to steric effects and a slowdown of the solvent dynamics. These effects are concentration-dependent and possibly unattainable at therapeutic-relevant concentrations. These results suggest that the aggregation inhibition activity of RSV and GA in vitro should involve, instead, either the non-covalent binding to oligomeric intermediates or the stabilization of the monomer and/or oligomers through the formation of covalent bonds of the respective quinones with α-syn. In addition, the enhanced aggregation tendency of the peptides observed here could be associated with the formation of non-toxic oligomers, reported for some polyphenols.
format Online
Article
Text
id pubmed-10197135
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-101971352023-05-20 Mechanistic Insights into Polyphenols’ Aggregation Inhibition of α-Synuclein and Related Peptides Martins, G. F. Nascimento, C. Galamba, N. ACS Chem Neurosci [Image: see text] While several polyphenols were found to either inhibit or modulate the aggregation of proteins implicated in neurodegenerative diseases, such as Parkinson’s disease (PD), discrepant action mechanisms have been reported. This, in addition to some polyphenols’ pan-assay interference compounds’ reputation, casts some doubts concerning their therapeutic relevance. Here, we studied, through molecular dynamics and enhanced sampling methods, the aggregation of 11-mer peptides from the non-amyloid-β component, an aggregation-prone domain of α-synuclein (α-syn) implicated in PD and other synucleinopathies, in neat water and aqueous solutions of resveratrol (RSV) and gallic acid (GA). Further, simulations of the complete protein were carried out in aqueous urea, RSV, and GA solutions. Our results show that peptide aggregation is not disrupted by either phenolic compound. Thus, instead, intrusion of RSV and GA in the inter-peptide region induces a peptide–peptide re-orientation, favoring terminal interactions that manifest in the formation of barrierless solvent-separated configurations. Moreover, although the (poly)phenols induce a pronounced peptide dewetting at high concentrations, β-sheet-rich regions, a hallmark of α-syn aggregation, are not disrupted. Thus, our results indicate that, if anything, RSV and GA delay or modulate peptide aggregation at high concentrations via the stabilization of solvent-separated conformations as opposed to aggregation inhibition. Structural analysis of the full protein, however, shows that the (poly)phenols induce more extended conformations of α-syn, similar to urea, possibly also influencing its aggregation propensity. However, opposite to urea, the (poly)phenols reduce α-syn’s conformational space, likely due to steric effects and a slowdown of the solvent dynamics. These effects are concentration-dependent and possibly unattainable at therapeutic-relevant concentrations. These results suggest that the aggregation inhibition activity of RSV and GA in vitro should involve, instead, either the non-covalent binding to oligomeric intermediates or the stabilization of the monomer and/or oligomers through the formation of covalent bonds of the respective quinones with α-syn. In addition, the enhanced aggregation tendency of the peptides observed here could be associated with the formation of non-toxic oligomers, reported for some polyphenols. American Chemical Society 2023-04-26 /pmc/articles/PMC10197135/ /pubmed/37125909 http://dx.doi.org/10.1021/acschemneuro.3c00162 Text en © 2023 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by/4.0/Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Martins, G. F.
Nascimento, C.
Galamba, N.
Mechanistic Insights into Polyphenols’ Aggregation Inhibition of α-Synuclein and Related Peptides
title Mechanistic Insights into Polyphenols’ Aggregation Inhibition of α-Synuclein and Related Peptides
title_full Mechanistic Insights into Polyphenols’ Aggregation Inhibition of α-Synuclein and Related Peptides
title_fullStr Mechanistic Insights into Polyphenols’ Aggregation Inhibition of α-Synuclein and Related Peptides
title_full_unstemmed Mechanistic Insights into Polyphenols’ Aggregation Inhibition of α-Synuclein and Related Peptides
title_short Mechanistic Insights into Polyphenols’ Aggregation Inhibition of α-Synuclein and Related Peptides
title_sort mechanistic insights into polyphenols’ aggregation inhibition of α-synuclein and related peptides
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197135/
https://www.ncbi.nlm.nih.gov/pubmed/37125909
http://dx.doi.org/10.1021/acschemneuro.3c00162
work_keys_str_mv AT martinsgf mechanisticinsightsintopolyphenolsaggregationinhibitionofasynucleinandrelatedpeptides
AT nascimentoc mechanisticinsightsintopolyphenolsaggregationinhibitionofasynucleinandrelatedpeptides
AT galamban mechanisticinsightsintopolyphenolsaggregationinhibitionofasynucleinandrelatedpeptides